Prostate Health Index (phi)

ورودی‌های بالینی بیمار

حداقل ۲ — حداکثر ۱۰

حداقل ۰.۱ — حداکثر ۱۰

حداقل ۱ — حداکثر ۵۰۰۰

حداقل ۵۰ — حداکثر ۱۰۰

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
phi
—index
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Below operating point0–27
  • At/above operating point27–1000000000
Direct Clinical Answer

The Prostate Health Index (phi) calculates evaluating lower urinary tract symptoms, nephrolithiasis burden, and prostate cancer risk. Key inputs include total psa. Scores guide initiating medical expulsive or alpha-blocker therapy, ordering renal imaging, or scheduling surgical intervention. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

The Beckman Coulter Prostate Health Index combines total PSA, free PSA and [-2]proPSA: phi = (p2PSA / fPSA) x sqrt(tPSA). Validated for men >=50 with PSA 4-10 ng/mL and non-suspicious DRE.

Clinical Indication

The Prostate Health Index (phi) is indicated for bedside clinical practice to support The Beckman Coulter Prostate Health Index combines total PSA, free PSA and [-2]proPSA: phi = (p2PSA / fPSA) x sqrt(tPSA). Validated for men >=50 with PSA 4-10 ng/mL and non-suspicious DRE.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with renal colic, hematuria, benign prostatic hyperplasia (BPH), or urogenital malignancies. Clinical application is indicated across Urology clinics, shock wave lithotripsy suites, and acute urologic surgical services.

Limitations & Contraindications

Serum PSA levels can be transiently elevated by acute prostatitis, urinary retention, or recent instrumentation.

Clinical Pearls & Action Plan

Obstructive urolithiasis complicated by upper urinary tract infection represents a surgical emergency requiring urgent decompression. Guideline pearl: In the pivotal trial a phi of 27.0 gave 31% specificity at 90% sensitivity; risk rises continuously with phi..

Formula & Variables:

phi = (p2PSA [pg/mL] / fPSA [ng/mL]) x sqrt(tPSA [ng/mL]). NOTE the intentional unit mix: p2PSA in pg/mL, fPSA and tPSA in ng/mL.

Input Parameters

NameTypeRequiredDescription
total_psafloatYesTotal PSA (ng/mL)
free_psafloatYesFree PSA (ng/mL)
p2psafloatYes[-2]proPSA (pg/mL)
age_yearsintegerYesAge (years, >=50 for validated use)

Score Interpretation & Guidance

RangeStageDescription
0–27Below operating pointphi <27
27–1000000000At/above operating pointphi >=27

Evidence-Based References (EBM)

  • Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185(5):1650-1655.
  • FDA approval 2012: phi for men >=50 years, tPSA 4-10 ng/mL, non-suspicious DRE.

Related calculators